Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ients with evaluable GCase data, and 5 of the 6 patients without a clear increase were either in the lowest dose cohort or the cohort dosed least frequently. As expected in this short term study, the levels of relevant hematological markers of Gaucher disease remained stable.

Amicus has amended the protocol for the 6-month Phase 2 clinical trial of Plicera patients naive to ERT to include modified doses and dose regimens. Amicus expects the results of this study to be available in 2009. In addition, in the second half of 2008, the Company expects to initiate a longer-term study in individuals switching from ERT to Plicera.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic drug candidate being developed for the treatment of Pompe disease. At the ACMG meeting in March, clinical investigators presented encouraging results from an ex vivo response study in cells from patients with Pompe disease as well as three Phase 1 clinical trials of AT2220 in healthy volunteers. The ex vivo response study was designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells from these samples where then treated with AT2220. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T > G. Data from the Phase 1 trials in a total of 72 healthy volunteers showed that AT2220 was generally safe and well tolerated at all doses.

In the second quarter of 2008, Amicus plans to initiate a Phase 2 clinical trial of AT2220 in patients with Pompe disease. The Company also plans to consider the initiation of a clinical trial of AT2220-ERT combination treatment in Pompe patients later in 2008
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Oven Industries Inc. ... ramp/soak capabilities. The 5R6-900 benchtop controller has many outstanding ... can be plugged into the wall as a self-contained ... This distinctive detail makes the device unique, as well ... laboratory temperature controller can also be used universally, which ...
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific Shore ... based products across a broad range of product ... retained investor relations firm, BlueWater Advisory Group, to ... to trading process, and to direct the company,s ... Matthew Mills , ...
(Date:5/20/2013)... With bed bugs' presence come problems in various ... need to be eliminated, one must make sure that the ... And so to help bed bug sufferers get that done, ... bed bugs without using harmful pesticides. In it, the ... Bed Bug Bully. , According to My Cleaning Products, contrary ...
(Date:5/20/2013)... , May 20, 2013   Flexion Therapeutics , ... W. Driscoll to its management team as ... years of financial management experience with biotechnology and medical ... Driscoll was chief financial officer for Novavax (NASDAQ: ... secured more than $250 million through a combination of ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Pacific Shore Holdings Retains Investor Relations Firm 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2
... Corporation (Nasdaq: ROCM ) will announce quarterly results ... Company will then,hold a quarterly conference call to discuss ... central daylight time (5:00 p.m. eastern time)., This ... accessed at,Rochester Medical,s website at http://www.rocm.com . To ...
... American Oriental,Bioengineering, Inc. (NYSE: AOB ) today ... results on Monday, August 11, 2008, after the,market closes., ... 5:00 pm ET on August 11,2008 to discuss its ... by dialing 1-800-599-9816 or 1-617-847-8705 for,international callers, access code: ...
... Radiofrequency ... Surgical Technologies -, PALO ALTO, Calif., July 24 ... new tissue dissection system,based on a proprietary technology, today announced that ... to market its,PEAK(R) Surgery System for use in general surgery. The ...
Cached Biology Technology:Rochester Medical Announces Third Quarter 2008 Earnings Conference Call July 31, 2008 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 4
(Date:5/20/2013)... Foundation (NSF) planning grant will help establish the Center ... of the University of Illinois at Urbana-Champaign and Worcester ... be devoted to research in drying moist, porous materials ... paper products; chemical products; textiles; and biopharmaceuticals," said Hao ... and human nutrition and the Illinois site director. , ...
(Date:5/19/2013)... novel study reports that white men and women of ... (hallux valgus) and lesser toe deformities, including hammer or ... to estimate the heritability of foot disorders in humansappear ... published by Wiley on behalf of the American College ... as many as 60% of older adults have foot ...
(Date:5/18/2013)... (May 18, 2013) Research presented today at Digestive ... research, with findings about the impact of coffee on ... , While coffee consumption recently has been associated with ... even a few more cups of java each month ... liver disease. Researchers at the Mayo Clinic, Rochester, MN, ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Blame your parents for bunion woes 2Coffee consumption associated with reduced risk of autoimmune liver disease 2
... goes the cynical saying with television and newspaper editors. In other ... the big story on the front page. So one might ... and unhappy types of words like "war," " funeral," "cancer," ... "hero." Or take Twitter. A popular image of what people ...
... BOSTON, January 12, 2012: A research collaboration between ... Harvard University and Children,s Hospital Boston has developed ... selectively deliver drugs to the cells of the ... testing and development before being ready for clinical ...
... Illinois researchers have shown that by tuning the ... nanoantennas, these nano-scale structures allow for dexterous optical ... "Nanoantennas are extremely popular right now because ... in small areas," explained Kimani Toussaint, Jr., an ...
Cached Biology News:We may be less happy, but our language isn't 2We may be less happy, but our language isn't 3New 'smart' nanotherapeutics can deliver drugs directly to the pancreas 2Optical nanoantennas enable efficient multipurpose particle manipulation 2
... Kit, 50 purifications. Allows rapid purification ... removal of unincorporated CyDye label and ... yields of labeled cDNA probe. ... labeled by either direct incorporation or ...
... reagents for the isolation of genomic DNA. ... the isolation of genomic DNA from blood. ... the isolation of genomic DNA from plants. ... be used for restriction endonuclease digestion Southern ...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Biology Products: